This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Jan;21(1):15-16.

doi: 10.1038/d41573-021-00194-5.

The market for ulcerative colitis

Rami Al-Horani, Eleonora Spanudakis, Bashar Hamad

PMID: 34815547
DOI: 10.1038/d41573-021-00194-5

The market for ulcerative colitis

Rami Al-Horani et al. Nat Rev Drug Discov. 2022 Jan.

. 2022 Jan;21(1):15-16.

doi: 10.1038/d41573-021-00194-5.

Authors

Rami Al-Horani, Eleonora Spanudakis, Bashar Hamad

PMID: 34815547
DOI: 10.1038/d41573-021-00194-5

No abstract available

PubMed Disclaimer

Similar articles

Intensification of maintenance therapy with infliximab in ulcerative colitis.
Casellas F. Casellas F. Rev Esp Enferm Dig. 2015 Sep;107(9):525-6. Rev Esp Enferm Dig. 2015. PMID: 26334457 No abstract available.
Table: drugs for ulcerative colitis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Jul 2;60(1550):e114. Med Lett Drugs Ther. 2018. PMID: 30036353 No abstract available.
Infliximab for ulcerative colitis.
Actis GC. Actis GC. Am J Gastroenterol. 2003 Mar;98(3):709. doi: 10.1111/j.1572-0241.2003.07312.x. Am J Gastroenterol. 2003. PMID: 12650824 No abstract available.
Balsalazide disodium for the treatment of ulcerative colitis.
Patil SA, Moss AC. Patil SA, et al. Expert Rev Gastroenterol Hepatol. 2008 Apr;2(2):177-84. doi: 10.1586/17474124.2.2.177. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072352 Review.
[Biologics treatment for ulcerative colitis].
Nagahori M, Fujii T, Saito E, Ohtsuka K, Watanabe M. Nagahori M, et al. Nihon Shokakibyo Gakkai Zasshi. 2013 Nov;110(11):1909-15. Nihon Shokakibyo Gakkai Zasshi. 2013. PMID: 24189818 Review. Japanese. No abstract available.

See all similar articles

Cited by

RISE-MX, a real-world study of patients with moderate/severe inflammatory bowel disease returning for hospital follow-up in Mexico: baseline demographics and clinical characteristics, treatment and disease status.
Martínez-Vázquez MA, Bosques-Padilla FJ, Miranda-Cordero RM, Yamamoto-Furusho JK. Martínez-Vázquez MA, et al. Therap Adv Gastroenterol. 2025 Feb 17;18:17562848251318857. doi: 10.1177/17562848251318857. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 39968532 Free PMC article.
Terminalia bellirica Fruit Extract Alleviates DSS-Induced Ulcerative Colitis by Regulating Gut Microbiota, Inflammatory Mediators, and Cytokines.
Li YY, Cui Y, Dong WR, Liu TT, Zhou G, Chen YX. Li YY, et al. Molecules. 2023 Jul 31;28(15):5783. doi: 10.3390/molecules28155783. Molecules. 2023. PMID: 37570753 Free PMC article.
P2Y₁₄ receptors: a new target for treating ulcerative colitis.
Zuo YQ, Tang Y. Zuo YQ, et al. Purinergic Signal. 2024 May 9. doi: 10.1007/s11302-024-10017-y. Online ahead of print. Purinergic Signal. 2024. PMID: 38722454 No abstract available.
Integrated Analysis of Ferroptosis and Immune Infiltration in Ulcerative Colitis Based on Bioinformatics.
Cai D, Hu W, Cai Y, Fang T, Chen X. Cai D, et al. J Inflamm Res. 2025 Mar 10;18:3535-3549. doi: 10.2147/JIR.S501651. eCollection 2025. J Inflamm Res. 2025. PMID: 40093944 Free PMC article.
Dynamic Changes in Gut Microbiome of Ulcerative Colitis: Initial Study from Animal Model.
Gu W, Zhang L, Han T, Huang H, Chen J. Gu W, et al. J Inflamm Res. 2022 Apr 24;15:2631-2647. doi: 10.2147/JIR.S358807. eCollection 2022. J Inflamm Res. 2022. PMID: 35494313 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

SC3 GM131986/GM/NIGMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information